Northwest Capital Management Inc Sells 852 Shares of Amgen Inc. $AMGN

Northwest Capital Management Inc cut its stake in Amgen Inc. (NASDAQ:AMGN) by 29.0% in the second quarter, HoldingsChannel.com reports. The fund owned 2,084 shares of the medical research company’s stock after selling 852 shares during the period. Northwest Capital Management Inc’s holdings in Amgen were worth $582,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of AMGN. Brighton Jones LLC raised its position in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the period. GAMMA Investing LLC raised its position in shares of Amgen by 40.2% during the first quarter. GAMMA Investing LLC now owns 11,753 shares of the medical research company’s stock worth $3,662,000 after purchasing an additional 3,369 shares during the period. Sound Income Strategies LLC raised its position in shares of Amgen by 6.4% during the first quarter. Sound Income Strategies LLC now owns 834 shares of the medical research company’s stock worth $260,000 after purchasing an additional 50 shares during the period. Acropolis Investment Management LLC raised its position in shares of Amgen by 7.8% during the first quarter. Acropolis Investment Management LLC now owns 1,097 shares of the medical research company’s stock worth $342,000 after purchasing an additional 79 shares during the period. Finally, Stewardship Advisors LLC raised its position in shares of Amgen by 4.9% during the first quarter. Stewardship Advisors LLC now owns 893 shares of the medical research company’s stock worth $278,000 after purchasing an additional 42 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 0.8%

AMGN stock opened at $292.40 on Tuesday. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The business has a 50 day moving average price of $286.58 and a two-hundred day moving average price of $287.33. The company has a market cap of $157.42 billion, a price-to-earnings ratio of 23.91, a P/E/G ratio of 2.52 and a beta of 0.49. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $335.88.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. The firm had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business’s revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date was Friday, August 22nd. Amgen’s dividend payout ratio (DPR) is currently 77.84%.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.69% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on AMGN shares. UBS Group dropped their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings upgraded Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Raymond James Financial began coverage on Amgen in a report on Wednesday, September 3rd. They set a “market perform” rating for the company. Finally, Citigroup increased their price objective on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a report on Wednesday, September 24th. Eight equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus price target of $309.42.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.